BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients

Phase 1

Completed

Conditions: Systemic Lupus Erythematosus
Psoriasis
Inflammatory Bowel Diseases
Arthritic Psoriasis

Interventions: Drug: BMS-986165
Drug: Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)

First Posted Date: 2017-08-25

Last Posted Date: 2020-03-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 49

Registration Number: NCT03262727

Locations: 🇺🇸
Miami Research Associates, Miami, Florida, United States

The Effect of BMS-986195 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: BMS-986195
Drug: Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)

First Posted Date: 2017-08-25

Last Posted Date: 2020-03-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 58

Registration Number: NCT03262740

Locations: 🇺🇸
Miami Research Associates, South Miami, Florida, United States
🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States

A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation

Phase 1

Completed

Conditions: Inflammatory Bowel Diseases
Systemic Lupus Erythematosus
Arthritic Psoriasis
Psoriasis

Interventions: Drug: BMS-986165 Capsule
Drug: BMS-986165 Tablet

First Posted Date: 2017-08-18

Last Posted Date: 2020-02-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 49

Registration Number: NCT03254784

Locations: 🇺🇸
PRA Health Sciences, Lenexa, Kansas, United States

An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus

Phase 2

Completed

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: BMS-986165
Other: Placebo

First Posted Date: 2017-08-17

Last Posted Date: 2022-12-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 363

Registration Number: NCT03252587

Locations: 🇺🇸
Local Institution - 0022, Decatur, Georgia, United States
🇺🇸
Local Institution - 0023, El Cajon, California, United States
🇺🇸
Little Rock Diagnostic Clinic, Little Rock, Arkansas, United States

and more 176 locations

A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors

Phase 1

Terminated

Conditions: Cancer
Tumors
Neoplasm
Malignancy

Interventions: Drug: BMS-986226
Biological: Ipilimumab
Biological: Nivolumab
Biological: Tetanus Vaccine

First Posted Date: 2017-08-16

Last Posted Date: 2023-02-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 80

Registration Number: NCT03251924

Locations: 🇺🇸
Local Institution - 0001, Philadelphia, Pennsylvania, United States
🇺🇸
Local Institution - 0012, Saint Louis, Missouri, United States
🇺🇸
Local Institution - 0002, Hackensack, New Jersey, United States

and more 10 locations

Pharmacokinetics and Metabolism Study in Healthy Male Participants

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: BMS-986205

First Posted Date: 2017-08-11

Last Posted Date: 2017-11-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 9

Registration Number: NCT03247283

Locations: 🇺🇸
Covance Clinical Research Unit, Inc., Madison, Wisconsin, United States

A Study of BMS-986195 in Healthy Male Subjects

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: BMS-986195

First Posted Date: 2017-08-10

Last Posted Date: 2018-01-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 24

Registration Number: NCT03245515

Locations: 🇳🇱
Local Institution, Groningen, Netherlands

A Study of Safety, Tolerability, and the Effects Two ND-L02-s0201 Have on the Body

Phase 1

Completed

Conditions: Fibrosis

Interventions: Drug: ND-L02-s0201

First Posted Date: 2017-08-07

Last Posted Date: 2017-08-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 12

Registration Number: NCT03241264

To Evaluate the Safety and Pharmacokinetics of BMS-986177 in Healthy Japanese Participants

Phase 1

Completed

Conditions: Thrombosis

Interventions: Drug: BMS-986177
Other: Matched Placebo

First Posted Date: 2017-07-21

Last Posted Date: 2018-06-01

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 33

Registration Number: NCT03224260

Locations: 🇺🇸
West Coast Clinical Trials, Anaheim, California, United States

A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC

Phase 3

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Biological: Ipilimumab
Biological: Nivolumab
Drug: Carboplatin
Drug: Paclitaxel
Drug: Pemetrexed
Drug: Cisplatin

First Posted Date: 2017-07-12

Last Posted Date: 2024-12-24

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 719

Registration Number: NCT03215706

Locations: 🇺🇸
Local Institution - 0091, Wichita, Kansas, United States
🇺🇸
Local Institution - 0004, Lexington, Kentucky, United States
🇦🇺
Local Institution - 0086, Gosford, New South Wales, Australia

and more 113 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy